宫颈癌两种新辅助化疗方案的药物经济学评价

Pharmacoeconomics Evaluation of Two Different Neoadjuvant Chemotherapy Regimens in the Treatment of Cervical Cancer

目的利用药物经济学方法评价两种新辅助化疗方案治疗宫颈癌的临床疗效和效果。方法回顾性分析我院妇科2012年1月~2013年12月确诊为宫颈鳞癌Ⅱa、Ⅱb期并接受新辅助化疗的住院患者病历46份,按化疗方案分两组,采用成本-效果分析法对两种方案进行药物经济学评价。TP组,采用紫杉醇+顺铂方案;TC组,采用紫杉醇+卡铂方案。结果 TP、TC组有效率分别为70.00%、69.23%(P>0.05),平均成本分别为5173.22元、4743.52元(P>0.05);TP组每增加1个单位效果,需多花428.71元;两组之间不良反应发生率无显著性差异(P>0.05)。结论从成本-效果分析,紫杉醇合用卡铂方案是作为宫颈癌新辅助化疗较佳的方案。

OBJECTIVE To evaluate two neoadjuvant chemotherapy regimens against cervical cancer by the method of pharmacoeconomics. METHODS Totally 46 case of cervical cancer in stage Ⅱa and Ⅱb were diagnosed by pathlogy in our hospital from January 2012 to December 2013,and retrospective analysis was applied. Group TP,paclitaxel combined cisplatin; Group TC,paclitaxel combined carboplatin. RESULTS The effective rates of Group TP and Group TC were 70. 00% and 69. 23%（P〈0. 05）,The average treatment cost of group TP was 5173. 22 yuan and the average treatment cost of group TC was 4743. 52 yuan（P〉0. 05）; Based on group TC,for each unit of efficacy increased,costs in group TP was increased 428. 71 yuan. There was no statistically significant difference in the adverse reactions between them（P〉0. 05）. CONCLUSION Neoadjuvant chemotherapy of paclitaxel combined carboplatin in the treatment of cervical cancer is more cost-effective than paclitaxel combined cisplatin.